Screener
Immunome IMNM Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $582,693 | $653,482 |
| Prepaid expenses and other current assets | 11,616 | 7,295 |
| Total current assets | 594,309 | 660,777 |
| Property and equipment, net | 17,081 | 14,636 |
| Operating right-of-use assets | 2,828 | 2,978 |
| Restricted cash | 210 | 210 |
| Other long-term assets | 5,364 | 4,587 |
Item 1. Financial Statements.
FAQ
- What is Immunome's total current assets?
- Immunome (IMNM) reported total current assets of $594.31M in Q1 2026.
- How has Immunome's total current assets changed year-over-year?
- Immunome's total current assets increased by 83.9% year-over-year, from $323.13M to $594.31M.
- What is the long-term trend for Immunome's total current assets?
- Over 5 years (2020 to 2025), Immunome's total current assets has grown at a 72.8% compound annual growth rate (CAGR), from $42.89M to $660.78M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Immunome's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude